
  
    
      
        Background_NNP
        Progesterone_NNP derived_VBD from_IN the_DT corpus_NN luteum_NN (_( CL_NNP )_) is_VBZ
        required_VBN for_IN the_DT establishment_NN and_CC maintenance_NN of_IN a_DT
        suitable_JJ uterine_NN environment_NN during_IN early_JJ pregnancy_NN [_NN 1_CD 2_CD ]_NN
        ._. Inappropriate_NNP luteal_NN function_NN (_( 
        i_NNP ._. e_SYM ._. luteal_NN insufficiency_NN )_) may_MD
        contribute_VB to_TO the_DT high_JJ incidence_NN of_IN spontaneous_JJ abortions_NNS
        that_WDT occur_VBP early_RB in_IN mammalian_JJ pregnancies_NNS [_NN 3_CD ]_NN ._. In_IN most_JJS
        species_NNS ,_, the_DT luteolytic_JJ cascade_NN ,_, starting_VBG with_IN loss_NN of_IN
        progesterone_NN production_NN and_CC followed_VBN by_IN tissue_NN regression_NN (_(
        
        i_NNP ._. e_SYM ._. apoptosis_NNS )_) ,_, is_VBZ initiated_VBN by_IN
        prostaglandin_NN F_NN 
        2_CD α_NN (_( PGF_NNP 
        2_CD α_NN )_) 
        in_IN vivo_NN [_NN 4_CD ]_NN ._. However_RB ,_, this_DT process_NN
        can_MD only_RB be_VB partially_RB recapitulated_JJ 
        in_IN vitro_NN using_VBG primary_JJ cultures_NNS of_IN
        steroidogenic_JJ cells_NNS ._. Gonadotropin-induced_NNP progesterone_NN
        production_NN is_VBZ attenuated_JJ by_IN PGF_NNP 
        2_CD α_NN treatment_NN ,_, but_CC this_DT prostanoid_NN does_VBZ
        not_RB activate_VBP apoptosis_NNS of_IN bovine_JJ steroidogenic_JJ cells_NNS 
        in_IN vitro_NN [_NN 8_CD ]_NN ._. These_DT findings_NNS
        helped_VBD develop_VB the_DT concept_NN that_IN additional_JJ factors_NNS ,_, such_JJ as_IN
        immune_JJ cells_NNS [_NN 5_CD 6_CD 7_CD ]_NN or_CC cytokines_NNS [_NN 7_CD 8_CD ]_NN ,_, contribute_VB to_TO
        the_DT luteolytic_JJ process_NN ._. Indeed_RB ,_, tumor_NN necrosis_NNS factor_NN α_NN
        (_( TNFα_NNP )_) ,_, interferon_NN gamma_NN (_( IFNγ_NNP )_) and_CC /_NN or_CC interleukin-_NN 1_CD beta_NN
        (_( IL-_NNP 1_CD β_NN )_) have_VBP all_DT been_VBN shown_VBN to_TO reduce_VB gonadotrophin-induced_JJ
        progesterone_NN synthesis_NN in_IN a_DT number_NN of_IN species_NNS [_NN 8_CD 9_CD 10_CD 11_CD
        12_CD ]_NN ,_, and_CC TNFα_NNP and_CC IFNγ_NNP are_VBP known_VBN to_TO increase_VB PGF_NNP 
        2_CD α_NN production_NN by_IN steroidogenic_JJ cells_NNS [_NN
        13_CD 14_CD 15_CD ]_NN ._. Steroidogenic_NNP cell_NN apoptotic_JJ paradigms_NNS are_VBP
        activated_VBN by_IN cytokines_NNS generated_VBN by_IN several_JJ cell_NN types_NNS
        within_IN the_DT CL_NNP ,_, including_VBG immune_JJ cells_NNS and_CC endothelial_NN cells_NNS
        [_NN 7_CD 11_CD 16_CD ]_NN ._. The_DT synergistic_JJ actions_NNS of_IN IFNγ_NNP and_CC TNFα_NNP ,_, for_IN
        example_NN ,_, induce_VB steroidogenic_JJ cell_NN apoptosis_NNS [_NN 13_CD 17_CD ]_NN ,_, as_IN
        does_VBZ soluble_JJ Fas_NNP ligand_NN (_( FasL_NNP )_) [_NN 18_CD 19_CD 20_CD 21_CD 22_CD 23_CD 24_CD 25_CD 26_CD
        ]_NN ._. Furthermore_RB ,_, several_JJ acute_JJ intracellular_NN signaling_VBG
        events_NNS either_CC required_VBN for_IN ,_, or_CC associated_VBN with_IN ,_, the_DT
        functional_JJ and_CC structural_JJ aspects_NNS of_IN luteal_NN regression_NN have_VBP
        been_VBN mapped_VBN using_VBG 
        in_IN vitro_NN steroidogenic_JJ cell_NN cultures_NNS
        [_NN 8_CD 27_CD 28_CD ]_NN ._.
        The_DT microvasculature_NN of_IN the_DT CL_NNP is_VBZ thought_VBN to_TO be_VB the_DT
        first_JJ structure_NN to_TO undergo_VB degeneration_NN via_IN apoptosis_NNS
        during_IN luteolysis_NNS [_NN 2_CD 8_CD ]_NN ._. In_IN contrast_NN to_TO information_NN
        available_JJ on_IN steroidogenic_JJ cells_NNS of_IN the_DT CL_NNP ,_, a_DT gap_NN exists_VBZ in_IN
        our_PRP$ understanding_NN of_IN the_DT factors_NNS and_CC their_PRP$ associated_VBN
        signaling_VBG pathways_NNS that_WDT initiate_VBP apoptosis_NNS in_IN the_DT vascular_NN
        component_NN of_IN the_DT CL_NNP ._. Elevated_NNP TNFα_NNP activity_NN may_MD play_VB a_DT role_NN
        in_IN the_DT apoptosis_NNS of_IN CL-derived_NNP microvascular_NN endothelial_NN
        (_( CLENDO_NNP )_) cells_NNS [_NN 29_CD ]_NN ._. TNFα_NNP is_VBZ known_VBN to_TO initiate_VB apoptosis_NNS
        in_IN diverse_JJ cell_NN types_NNS by_IN activating_VBG its_PRP$ cognate_NN receptor_NN ,_,
        TNF-RI_NNP ,_, a_DT cell_NN surface_NN receptor_NN and_CC member_NN of_IN the_DT tumor_NN
        necrosis_NNS receptor_NN super_JJ family_NN (_( TNFRSF_NNP )_) ._. TNF-RI_NNP is_VBZ also_RB a_DT
        death_NN receptor_NN based_VBN on_IN the_DT presence_NN of_IN a_DT carboxy-terminal_JJ
        functional_JJ domain_NN known_VBN as_IN the_DT death_NN domain_NN ._. The_DT death_NN
        domain_NN serves_VBZ as_IN a_DT binding_JJ domain_NN for_IN cytoplasmic_JJ adapter_NN
        proteins_NNS ,_, which_WDT contain_VBP a_DT death_NN domain_NN and_CC a_DT death_NN effector_NN
        domain_NN (_( 
        i_NNP ._. e_SYM ._. Fas_NNP associated_VBN death_NN domain_NN ,_,
        FADD_NNP )_) [_NN 30_CD ]_NN ultimately_RB activating_VBG members_NNS of_IN the_DT caspase_NN
        family_NN resulting_VBG in_IN apoptosis_NNS ._. Activation_NNP of_IN TNFRI_NNP
        initiates_NNS stress-activated_JJ pathways_NNS ,_, which_WDT often_RB are_VBP
        associated_VBN with_IN the_DT onset_NN of_IN apoptosis_NNS in_IN a_DT cell_NN specific_JJ
        fashion_NN ._.
        Of_IN interest_NN to_TO these_DT studies_NNS are_VBP the_DT three_CD subfamilies_NNS
        within_IN the_DT mitogen-activated_JJ protein_NN kinase_NN (_( MAPK_NNP )_)
        superfamily_RB including_VBG the_DT extracellular_NN signal-related_JJ
        kinases_NNS (_( ERKs_NNP )_) ,_, p_NN 38_CD and_CC c-jun_JJ N-_NNP terminal_NN kinases_NNS (_( JNKs_NNP )_) [_NN
        31_CD ]_NN ._. TNFα_NNP is_VBZ one_CD of_IN many_JJ cytokines_NNS involved_VBN in_IN luteal_NN
        regression_NN ._. Although_IN the_DT mechanism_NN (_( s_VBZ )_) by_IN which_WDT cytokines_NNS
        induce_VB apoptosis_NNS vary_VBP among_IN cell_NN types_NNS ,_, it_PRP is_VBZ presumed_VBN that_IN
        it_PRP involves_VBZ either_CC an_DT increase_NN in_IN reactive_JJ oxygen_NN species_NNS
        (_( ROS_NNP )_) or_CC activation_NN of_IN stress-related_JJ signaling_VBG pathways_NNS ._.
        Interestingly_RB it_PRP has_VBZ been_VBN demonstrated_VBN that_IN rapid_JJ
        production_NN of_IN ROS_NNP in_IN endothelial_NN cells_NNS exposed_VBN to_TO TNFα_NNP is_VBZ
        mediated_JJ by_IN ceramide_NN [_NN 32_CD ]_NN ._. Ceramide_NNP is_VBZ a_DT central_JJ figure_NN
        in_IN the_DT sphingomyelin_NN pathway_NN ,_, which_WDT has_VBZ also_RB been_VBN linked_VBN to_TO
        stress_VB related_VBD signaling_VBG and_CC apoptosis_NNS [_NN 33_CD 34_CD ]_NN ._. This_DT
        report_NN provides_VBZ evidence_NN that_IN cytokines_NNS regulate_VB the_DT fate_NN
        of_IN CLENDO_NNP cells_NNS ._. In_IN the_DT first_JJ set_NN of_IN experiments_NNS ,_, we_PRP
        identified_VBD those_DT factors_NNS that_WDT initiate_VBP CLENDO_NNP cell_NN death_NN
        amongst_IN a_DT host_NN of_IN cytokines_NNS and_CC lipid_NN signaling_VBG molecules_NNS
        that_WDT mediate_VB various_JJ aspects_NNS of_IN luteal_NN structural_JJ
        regression_NN ._. In_IN a_DT second_JJ series_NN of_IN experiments_NNS ,_, we_PRP evaluated_VBD
        the_DT activation_NN of_IN several_JJ signal_NN transduction_NN pathways_NNS
        known_VBN to_TO coordinate_VB apoptosis_NNS in_IN other_JJ cell_NN types_NNS ._. A_DT
        working_VBG knowledge_NN of_IN the_DT collective_JJ signaling_VBG network_NN
        activated_VBN in_IN CLENDO_NNP cells_NNS by_IN specific_JJ death_NN stimuli_NNS is_VBZ
        essential_JJ to_TO complete_VB our_PRP$ understanding_NN of_IN how_WRB apoptosis_NNS is_VBZ
        controlled_VBN within_IN the_DT CL_NNP ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Cell_NNP culture_NN and_CC treatments_NNS
          Purified_NNP bovine_JJ CL-derived_NNP microvascular_NN endothelial_NN
          cell_NN populations_NNS were_VBD generated_VBN commercially_RB by_IN Cambrex_NNP
          Biosciences_NNP (_( BioWhittaker_NNP ,_, Walkersville_NNP ,_, MD_NNP )_) as_IN described_VBN
          in_IN detail_NN [_NN 35_CD ]_NN ._. In_IN the_DT present_JJ study_NN ,_, CLENDO_NNP cells_NNS
          from_IN frozen_VBN aliquots_NNS (_( passage_NN 3_LS )_) were_VBD seeded_VBN (_( 5_CD ,_, 000_CD
          cells_NNS /_NN cm_NN 2_LS )_) in_IN 6_CD -_: or_CC 24_CD -_: well_RB plates_NNS or_CC 10_CD cm_NN culture_NN
          dishes_NNS ._. The_DT cells_NNS were_VBD cultured_JJ in_IN EGM-_NNP 2_CD MV_NNP ,_, as_IN
          recommended_VBN by_IN the_DT supplier_NN with_IN progesterone_NN (_( 250_CD ng_NN /_NN ml_NN )_)
          and_CC 3_CD %_NN fetal_JJ bovine_JJ serum_NN added_VBD ._. Once_RB 90_CD %_NN confluency_NN was_VBD
          reached_VBN ,_, the_DT medium_NN was_VBD changed_VBN and_CC the_DT cultures_NNS were_VBD
          maintained_VBN in_IN serum-_NN and_CC growth_VB factor-free_JJ conditions_NNS
          (_( EBM-_NNP 2_CD medium_NN )_) for_IN 24_CD h_NN ._. Medium_NNP was_VBD then_RB removed_VBN once_RB
          again_RB and_CC fresh_JJ serum-_NN and_CC growth_VB factor-free_JJ medium_NN was_VBD
          applied_VBN ._. Cells_NNP were_VBD allowed_VBN to_TO equilibrate_NN for_IN a_DT minimum_NN
          of_IN 3_CD h_NN prior_RB to_TO treatment_NN ._. Treatment_NNP concentrations_NNS were_VBD
          based_VBN upon_IN previously_RB published_VBN 
          in_IN vitro_NN studies_NNS of_IN mixed_JJ luteal_NN
          cells_NNS [_NN 13_CD 14_CD 15_CD 17_CD 29_CD 36_CD ]_NN and_CC all_DT experiments_NNS were_VBD
          completed_VBN a_DT minimum_NN of_IN three_CD times_NNS ._.
          To_TO identify_VB putative_JJ luteolytic_JJ factors_NNS that_WDT initiate_VBP
          CLENDO_NNP cell_NN apoptosis_NNS ,_, cells_NNS were_VBD treated_VBN with_IN TNFα_NNP (_( 50_CD
          ng_NN /_NN ml_NN ;_: Upstate_NNP Biotechnology_NNP ,_, Inc_NNP ._. ;_: Lake_NNP Placid_NNP ,_, NY_NNP )_) ,_,
          bovine_JJ IFNγ_NNP (_( 200_CD IU_NNP /_NN ml_NN ;_: generous_JJ gift_NN from_IN Dr_NNP ._. Dale_NNP
          Godson_NNP ,_, Veterinary_JJ Infectious_NNP Disease_NNP Organization_NNP ,_,
          University_NNP of_IN Saskatchewan_NNP ,_, Saskatoon_NNP ,_, Saskatchewan_NNP ,_,
          Canada_NNP )_) ,_, sFasL_NN (_( 50_CD ng_NN /_NN ml_NN ;_: Oncogene_NNP ,_, LaJolla_NNP ,_, CA_NNP )_) ,_, mouse_NN
          Fas_NNP activating_VBG antibody_NN (_( Jo_NNP 2_CD ;_: 500_CD ng_NN /_NN ml_NN ;_: Pharmingen_NNP ,_, San_NNP
          Diego_NNP ,_, CA_NNP )_) ,_, human_JJ Fas_NNP activating_VBG antibody_NN (_( CH-_NNP 11_CD ;_: 500_CD
          ng_NN /_NN ml_NN ;_: Upstate_NNP Biotechnology_NNP ,_, Inc_NNP ._. ,_, Lake_NNP Placid_NNP ,_, NY_NNP )_) ,_, PGF_NNP
          
          2_LS α_NN (_( 1_CD μM_NN ;_: Sigma_NNP Chemical_NNP Company_NNP ;_: St_NNP ._.
          Louis_NNP ,_, MO_NNP )_) or_CC C_NNP 2_CD ceramide_NN (_( 50_CD μM_NN ;_: BioMol_NNP ;_: Plymouth_NNP
          Meeting_VBG ,_, PA_NNP )_) for_IN 24_CD ,_, 48_CD and_CC 72_CD h_NN ._. To_TO confirm_VB specificity_NN
          of_IN ceramide_NN in_IN triggering_VBG CLENDO_NNP cell_NN death_NN ,_, cultures_NNS
          were_VBD treated_VBN with_IN sphingosine-_NN 1_CD -_: phosphate_NN (_( S_NNP 1_CD P_NN ;_: 10_CD or_CC 50_CD
          μM_NN ;_: BioMol_NNP ;_: Plymouth_NNP Meeting_VBG ,_, PA_NNP )_) for_IN 48_CD h_NN ._. Furthermore_RB ,_,
          to_TO determine_VB if_IN S_NNP 1_CD P_NN attenuated_JJ ceramide-_NN or_CC TNFα-induced_NNP
          cell_NN death_NN ,_, CLENDO_NNP cells_NNS were_VBD first_JJ pretreated_JJ with_IN S_NNP 1_CD P_NN
          for_IN 30_CD min_NN ,_, followed_VBN by_IN application_NN of_IN ceramide_NN (_( 50_CD μM_NN )_)
          or_CC TNFα_NNP (_( 50_CD ng_NN /_NN ml_NN )_) ._. Finally_RB ,_, to_TO evaluate_VB the_DT impact_NN of_IN
          glutathione_NN (_( GSH_NNP )_) ,_, a_DT known_VBN inhibitor_NN of_IN TNFα-induced_NNP ROS_NNP
          formation_NN and_CC apoptosis_NNS ,_, on_IN CLENDO_NNP cell_NN survival_NN ,_, cells_NNS
          were_VBD pretreated_JJ with_IN control_NN media_NNS or_CC GSH_NNP (_( 10_CD mM_NN )_) for_IN 30_CD
          min_NN ,_, and_CC then_RB treated_VBN with_IN or_CC without_IN TNFα_NNP (_( 50_CD ng_NN /_NN ml_NN )_) for_IN
          48_CD h_NN ._.
          For_IN Western_JJ blot_NN analysis_NN ,_, CLENDO_NNP cells_NNS were_VBD treated_VBN
          with_IN TNFα_NNP (_( 50_CD ng_NN /_NN ml_NN )_) or_CC C_NNP 2_CD ceramide_NN for_IN 0_CD ,_, 2_CD ,_, 5_CD ,_, 10_CD ,_, 30_CD ,_,
          or_CC 60_CD min_NN ._. Cell_NNP lysates_NNS were_VBD collected_VBN and_CC assayed_JJ for_IN
          active_JJ MAPK_NNP family_NN members_NNS as_IN described_VBN below_IN ._. For_IN
          measurements_NNS of_IN ceramide_NN content_NN in_IN response_NN to_TO TNFα_NNP (_( 50_CD
          ng_NN /_NN ml_NN )_) treatment_NN ,_, pre-equilibrated_JJ cells_NNS were_VBD treated_VBN
          with_IN TNFα_NNP (_( 50_CD ng_NN /_NN ml_NN )_) for_IN 0_CD ,_, 2_CD ,_, 5_CD ,_, 10_CD or_CC 30_CD min_NN and_CC lipids_NNS
          were_VBD extracted_VBN as_IN described_VBN below_IN ._.
        
        
          Parameters_NNP of_IN apoptosis_NNS
          To_TO identify_VB apoptosis-inducing_JJ agents_NNS in_IN CLENDO_NNP cells_NNS ,_,
          culture_NN medium_NN was_VBD removed_VBN following_VBG treatments_NNS ,_, cells_NNS
          were_VBD washed_VBN one_CD time_NN with_IN ice_NN cold_JJ PBS_NNP ,_, and_CC fixed_VBD for_IN 10_CD
          min_NN with_IN 4_CD %_NN paraformaldehyde_NN ._. The_DT cells_NNS were_VBD rinsed_JJ one_CD
          time_NN with_IN PBS_NNP and_CC nuclei_NN stained_JJ by_IN placing_VBG 200_CD μl_NN
          glycerol_NN (_( 80_CD %_NN in_IN 1_CD X_NNP PBS_NNP )_) containing_VBG 2_CD μg_NN /_NN ml_NN Hoechst_NNP 33258_CD
          in_IN each_DT well_RB ._. While_IN pyknotic_JJ nuclei_NN were_VBD visible_JJ in_IN
          adherent_NN cells_NNS in_IN response_NN to_TO some_DT treatments_NNS ,_, we_PRP also_RB
          observed_VBD a_DT large_JJ number_NN of_IN dead_JJ ,_, floating_VBG cells_NNS as_IN
          confirmed_VBN by_IN trypan_NN blue_JJ staining_VBG ._. Thus_RB ,_, the_DT average_JJ
          number_NN of_IN non-apoptotic_JJ cells_NNS in_IN 10_CD fields_NNS was_VBD determined_VBN
          and_CC presented_VBN as_IN raw_JJ values_NNS ._. Biochemical_NNP analyses_NNS were_VBD
          employed_VBN to_TO verify_VB whether_IN or_CC not_RB cell_NN loss_NN was_VBD the_DT
          result_NN of_IN apoptosis_NNS ._.
          Oligonucleosomal_NNP DNA_NNP fragmentation_NN was_VBD used_VBN as_IN a_DT
          biochemical_JJ marker_NN of_IN endothelial_NN cell_NN apoptosis_NNS in_IN which_WDT
          cells_NNS were_VBD untreated_JJ for_IN 48_CD h_NN ,_, treated_VBN with_IN TNFα_NNP (_( 50_CD
          ng_NN /_NN ml_NN )_) for_IN 12_CD ,_, 24_CD or_CC 48_CD ,_, or_CC treated_VBD with_IN C_NNP 2_CD ceramide_NN (_( 50_CD
          μM_NN )_) for_IN 12_CD h_NN ._. Cells_NNP were_VBD scraped_JJ and_CC separated_JJ from_IN
          culture_NN medium_NN by_IN centrifugation_NN (_( 1200_CD rpm_NN ,_, 10_CD min_NN ,_, 4_CD °_NN C_NNP )_)
          and_CC DNA_NNP was_VBD isolated_VBN as_IN described_VBN [_NN 37_CD ]_NN ._. Following_VBG
          electrophoresis_NNS ,_, fragmented_JJ DNA_NNP (_( 5_CD μg_NN )_) was_VBD visualized_JJ by_IN
          ethidium_NN bromide_NN staining_VBG ._. To_TO provide_VB a_DT second_JJ source_NN of_IN
          biochemical_JJ evidence_NN that_IN TNFα_NNP induced_VBD apoptosis_NNS ,_,
          confluent_NN cultures_NNS of_IN CLENDO_NNP cells_NNS were_VBD incubated_JJ with_IN a_DT
          fluorogenic_JJ substrate_NN ,_, which_WDT detects_NNS caspase-_NN 3_CD activity_NN
          (_( 10_CD μM_NN ,_, DEVD_NNP sequence_NN ;_: Phi_NNP Phi_NNP Lux_FW ;_: OncoImmunin_NNP ,_, Inc_NNP ,_,
          College_NNP Park_NNP ,_, MD_NNP )_) at_IN 2_CD and_CC 8_CD h_NN after_IN TNFα_NNP treatment_NN for_IN
          30_CD min_NN ._. These_DT times_NNS were_VBD selected_VBN since_IN no_DT visible_JJ
          morphological_JJ signs_NNS (_( chromatin_NN condensation_NN or_CC formation_NN
          of_IN apoptotic_JJ bodies_NNS )_) of_IN apoptosis_NNS were_VBD evident_JJ until_IN
          after_IN 12_CD h_NN ._. Following_VBG the_DT incubation_NN ,_, cells_NNS were_VBD rinsed_JJ 3_CD
          times_NNS with_IN medium_NN and_CC analyzed_VBN by_IN fluorescent_NN microscopy_NN
          as_IN described_VBN [_NN 26_CD 38_CD ]_NN ._.
        
        
          Western_JJ blot_NN analysis_NN
          Protein_NNP lysates_NNS were_VBD collected_VBN for_IN Western_JJ blot_NN
          analysis_NN as_IN described_VBN elsewhere_RB [_NN 17_CD 35_CD 39_CD ]_NN ._. Briefly_NNP ,_,
          following_VBG separation_NN by_IN SDS-PAGE_NNP ,_, the_DT proteins_NNS (_( 20_CD
          μg_NN /_NN lane_NN )_) were_VBD transferred_VBN (_( 100_CD V_NNP ,_, 1_CD h_NN )_) to_TO polyvinylidene_NN
          difluoride_NN membranes_NNS ._. Nonspecific_NNP binding_JJ was_VBD blocked_VBN
          with_IN 5_CD %_NN fat_JJ free_JJ milk_NN in_IN TBST_NNP [_NN 50_CD mM_NN Tris-_NNP HCL_NNP (_( pH_NN 7_CD ._. 5_LS )_)
          0_CD ._. 15_CD NaCl_NNP ,_, 0_CD ._. 05_CD %_NN Tween-_NNP 20_CD ]_NN 1_CD h_NN at_IN room_NN temperature_NN ._.
          Membranes_NNP were_VBD then_RB incubated_JJ with_IN primary_JJ antibodies_NNS to_TO
          various_JJ MAPK_NNP family_NN members_NNS overnight_JJ at_IN 4_CD °_NN C_NNP
          (_( phospho-_NN ERK_NNP ,_, 1_CD :_: 5000_CD ,_, Promega_NNP ;_: Madison_NNP ,_, WI_NNP ;_: phospho-p_JJ 38_CD ,_,
          1_CD :_: 1000_CD ,_, New_NNP England_NNP Biolabs_NNP ,_, Beverly_NNP ,_, MA_NNP ;_: phospho-_NN JNK_NNP ,_,
          1_CD :_: 500_CD ,_, Santa_NNP Cruz_NNP Biotechnology_NNP ,_, Inc_NNP ._. ,_, Santa_NNP Cruz_NNP ,_, CA_NNP )_) ._.
          Previous_JJ studies_NNS have_VBP demonstrated_VBN that_IN these_DT antibodies_NNS
          recognize_VBP the_DT phosphorylated_JJ (_( active_JJ )_) forms_NNS of_IN
          extracellular-regulated_JJ kinase_NN (_( ERK_NNP )_) ,_, p_NN 38_CD ,_, and_CC
          Jun-_NNP N-_NNP terminal_NN kinase_NN (_( JNK_NNP )_) Membranes_NNP were_VBD then_RB washed_VBN (_( 3_CD
          ×_NN 5_CD min_NN each_DT )_) with_IN TBST_NNP buffer_NN and_CC incubated_JJ with_IN
          anti-rabbit_JJ IgG_NNP horseradish_NN peroxidase_NN conjugate_NN or_CC
          anti-mouse_JJ IgG_NNP horseradish_NN peroxidase_NN conjugate_NN (_( 1_CD :_: 2000_CD ;_:
          Santa_NNP Cruz_NNP Biotechnology_NNP ,_, Santa_NNP Cruz_NNP ,_, CA_NNP )_) for_IN 1_CD h_NN at_IN room_NN
          temperature_NN ._. The_DT membranes_NNS were_VBD washed_VBN with_IN TBST_NNP as_IN
          before_IN and_CC the_DT bound_VBN antibody_NN was_VBD detected_VBN using_VBG ECL_NNP
          reagents_NNS based_VBN on_IN the_DT manufacturer_NN 's_POS recommendations_NNS
          (_( Amersham_NNP ;_: Piscataway_NNP ,_, NJ_NNP )_) ._. X-_NNP ray_NN films_NNS were_VBD scanned_JJ and_CC
          band_NN intensity_NN was_VBD determined_VBN using_VBG a_DT Kodak-_NNP 1_CD D_NNP software_NN
          package_NN ._. Since_IN pJNK_NN ,_, pERK_NN and_CC panERK_NN appear_VBP in_IN two_CD
          isoforms_NNS ,_, both_DT bands_NNS were_VBD scanned_JJ together_RB ._. To_TO verify_VB
          equal_JJ protein_NN loading_NN membranes_NNS were_VBD then_RB stripped_VBN and_CC
          re-probed_JJ with_IN the_DT panERK_NN antibody_NN (_( 1_CD :_: 1000_CD ;_: Transduction_NNP
          Laboratories_NNPS ;_: Lexington_NNP ,_, KY_NNP )_) which_WDT recognizes_VBZ the_DT
          constitutively_RB expressed_VBN ERKs_NNP in_IN bovine_JJ CLENDO_NNP cells_NNS as_RB
          previously_RB described_VBD [_NN 35_CD ]_NN ._.
        
        
          Evaluation_NNP of_IN ceramide_NN production_NN in_IN response_NN to_TO
          TNFα_NNP
          The_DT amount_NN of_IN ceramide_NN generated_VBN by_IN CLENDO_NNP cells_NNS in_IN
          response_NN to_TO TNFα_NNP treatment_NN (_( 50_CD ng_NN /_NN ml_NN )_) was_VBD determined_VBN in_IN
          three_CD independent_JJ sets_NNS of_IN experiments_NNS via_IN the_DT diacyl_NN
          glycerol_NN kinase_NN assay_NN as_IN described_VBN [_NN 26_CD 40_CD ]_NN ._. Each_DT
          experiment_NN contained_VBD an_DT untreated_JJ control_NN that_WDT was_VBD used_VBN
          for_IN comparison_NN with_IN TNFα_NNP treated_VBD samples_NNS ._. Briefly_NNP ,_,
          membrane_NN lipids_NNS were_VBD extracted_VBN (_( 1_CD ml_NN methanol_NN ,_, 10_CD min_NN at_IN
          -_: 80_CD °_NN C_NNP )_) from_IN endothelial_NN cells_NNS immediately_RB following_VBG
          treatment_NN and_CC dried_VBD under_IN nitrogen_NN gas_NN ._. Lipids_NNP were_VBD
          subjected_VBN to_TO mild_JJ alkaline_NN hydrolysis_NNS and_CC dried_VBD under_IN
          nitrogen_NN gas_NN ._. Ceramide_NNP in_IN the_DT lipid_NN extracts_NNS were_VBD labeled_VBN
          with_IN [_NN 32_CD P-ATP_NNP ]_NN and_CC the_DT resulting_VBG products_NNS resolved_VBD using_VBG
          thin_JJ layer_NN chromatography_NN ._. Graded_NNP levels_NNS of_IN commercially_RB
          purified_JJ ceramides_NNS were_VBD employed_VBN as_IN a_DT standard_JJ curve_NN ._. The_DT
          band_NN in_IN each_DT lane_NN corresponding_JJ to_TO ceramide-_NN 1_CD -_: phosphate_NN
          was_VBD cut_VBN from_IN the_DT chromatography_NN plate_NN and_CC counted_VBN in_IN a_DT
          scintillation_NN counter_NN ._. Changes_NNS in_IN ceramide_NN production_NN in_IN
          response_NN to_TO TNFα_NNP treatment_NN were_VBD presented_VBN as_IN a_DT percentage_NN
          of_IN the_DT untreated_JJ control_NN value_NN ._.
        
        
          Statistics_NNS
          Assignment_NNP to_TO treatments_NNS was_VBD made_VBN at_IN random_JJ ._. Raw_NNP data_NNS
          were_VBD subjected_VBN to_TO least_JJS squares_NNS analysis_NN of_IN variance_NN
          followed_VBN by_IN Duncan_NNP 's_POS new_JJ multiple_JJ range_NN test_NN or_CC the_DT
          Student_NNP 
          t_NN -_: tests_NNS for_IN paired_VBN comparisons_NNS ._.
          The_DT results_NNS were_VBD expressed_VBN as_IN the_DT mean_JJ ±_NN SEM_NNP and_CC a_DT value_NN
          of_IN P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN significant_JJ ._.
        
      
      
        Results_NNS
        
          TNFα_NNP reduces_VBZ viability_NN of_IN CLENDO_NNP cells_NNS
          To_TO determine_VB which_WDT cytokines_NNS initiate_VBP apoptosis_NNS in_IN
          CLENDO_NNP cells_NNS we_PRP treated_VBD the_DT cells_NNS for_IN 48_CD h_NN with_IN TNFα_NNP ,_,
          IFNγ_NNP ,_, or_CC the_DT combination_NN of_IN the_DT two_CD ._. TNFα_NNP treatment_NN
          resulted_VBD in_IN a_DT significant_JJ reduction_NN in_IN CLENDO_NNP cell_NN
          viability_NN (_( 34_CD %_NN ,_, P_NN <_NN 0_CD ._. 05_CD )_) ,_, which_WDT was_VBD reduced_VBN (_( P_NN <_NN
          0_CD ._. 05_CD )_) an_DT additional_JJ 23_CD %_NN by_IN co-treatment_JJ with_IN IFNγ_NNP (_( Fig_NNP ._.
          1_LS a_DT )_) ._. Treatment_NNP with_IN IFNγ_NNP alone_RB showed_VBD no_DT statistical_JJ
          difference_NN in_IN viability_NN compared_VBN with_IN the_DT untreated_JJ
          control_NN during_IN the_DT first_JJ 48_CD h_NN of_IN treatment_NN ._. Although_IN Fas_NNP
          activating_VBG antibody_NN ,_, Jo_NNP 2_CD ,_, induces_VBZ apoptosis_NNS in_IN ovarian_NN
          surface_NN epithelial_NN cells_NNS [_NN 23_CD ]_NN ,_, Jo_NNP 2_CD had_VBD no_DT effect_NN on_IN
          CLENDO_NNP cell_NN survival_NN ._. Similarly_RB ,_, treatment_NN of_IN CLENDO_NNP
          cells_NNS with_IN the_DT luteolytic_JJ agent_NN ,_, PGF_NNP 
          2_CD α_NN ,_, for_IN 48_CD h_NN failed_VBD to_TO induce_VB
          apoptosis_NNS compared_VBN to_TO the_DT untreated_JJ control_NN ._.
          In_IN a_DT second_JJ group_NN of_IN experiments_NNS ,_, we_PRP observed_VBD that_IN
          CLENDO_NNP cells_NNS were_VBD resistant_JJ to_TO apoptosis_NNS when_WRB treated_VBN for_IN
          72_CD h_NN with_IN sFasL_NN or_CC the_DT human_JJ Fas_NNP activating_VBG antibody_NN
          CH-_NNP 11_CD ._. Interestingly_RB ,_, treatment_NN with_IN IFNγ_NNP for_IN 72_CD h_NN showed_VBD
          a_DT modest_JJ increase_NN (_( P_NN <_NN 0_CD ._. 05_CD )_) in_IN cell_NN death_NN compared_VBN to_TO
          the_DT untreated_JJ control_NN group_NN (_( Fig_NNP 1_CD b_SYM )_) ._.
          Treatment_NNP with_IN TNFα_NNP caused_VBD a_DT linear_JJ decrease_NN in_IN the_DT
          number_NN of_IN non-apoptotic_JJ CLENDO_NNP cells_NNS starting_VBG at_IN 24_CD h_NN and_CC
          continuing_VBG through_IN 72_CD h_NN of_IN treatment_NN (_( Fig_NNP ._. 2_LS a_DT )_) ._. CLENDO_NNP
          cells_NNS treated_VBN with_IN TNFα_NNP for_IN 12_CD h_NN showed_VBD no_DT significant_JJ
          difference_NN in_IN the_DT number_NN of_IN non-apoptotic_JJ cells_NNS compared_VBN
          with_IN the_DT 72_CD h_NN untreated_JJ control_NN ._. However_RB ,_, some_DT cells_NNS in_IN
          the_DT 12_CD h_NN group_NN showed_VBD early_JJ signs_NNS of_IN apoptosis_NNS in_IN that_DT
          pyknosis_NNS and_CC partitioning_VBG of_IN nuclei_NN were_VBD observed_VBN (_( not_RB
          shown_VBN )_) ._. To_TO provide_VB biochemical_JJ evidence_NN that_IN the_DT form_NN of_IN
          cell_NN death_NN observed_VBD was_VBD apoptosis_NNS ,_, assays_NNS for_IN
          oligonucleosomal_NN DNA_NNP fragmentation_NN and_CC caspase-_NN 3_CD activity_NN
          were_VBD performed_VBN ._. Oligonucleosomal_NNP DNA_NNP fragmentation_NN was_VBD
          evident_JJ 12_CD h_NN after_IN TNFα_NNP treatment_NN and_CC continued_VBD through_IN
          24_CD and_CC 48_CD h_NN (_( Fig_NNP ._. 2_LS b_SYM )_) ._. Caspase-_NNP 3_CD activity_NN (_( cleavage_NN of_IN
          Phi_NNP Phi_NNP Lux_FW )_) was_VBD easily_RB detected_VBN by_IN 8_CD h_NN after_IN TNFα_NNP
          treatment_NN ,_, and_CC was_VBD evident_JJ as_IN early_RB as_IN 2_CD h_NN (_( Fig_NNP 2_CD c_SYM ._. )_) ._.
        
        
          Ceramide_NNP is_VBZ generated_VBN in_IN response_NN to_TO TNFα_NNP treatment_NN
          and_CC kills_VBZ CLENDO_NNP cells_NNS
          Previous_JJ studies_NNS have_VBP shown_VBN that_IN TNFα_NNP ,_, like_IN other_JJ
          death_NN receptors_NNS ,_, stimulates_NNS the_DT accumulation_NN of_IN the_DT
          second_JJ messenger_NN ceramide_NN ,_, and_CC that_IN this_DT lipid_NN signaling_VBG
          molecule_NN can_MD serve_VB as_IN an_DT upstream_JJ activator_NN of_IN cell_NN
          stress_NN signaling_VBG pathways_NNS [_NN 41_CD ]_NN ._. Measurements_NNP of_IN total_JJ
          cellular_JJ ceramide_NN in_IN CLENDO_NNP cells_NNS revealed_VBD that_IN ceramide_NN
          levels_NNS were_VBD significantly_RB elevated_VBD (_( P_NN <_NN 0_CD ._. 05_CD )_) as_RB early_RB
          as_IN 2_CD min_NN following_VBG TNFα_NNP treatment_NN ,_, and_CC remained_VBD elevated_VBD
          through_IN 30_CD min_NN of_IN treatment_NN (_( Fig_NNP ._. 3_LS a_DT ._. )_) ._. Treatment_NNP of_IN
          CLENDO_NNP cells_NNS with_IN an_DT exogenous_JJ source_NN of_IN ceramide_NN (_( C_NNP 2_CD ,_, 50_CD
          μM_NN )_) caused_VBD a_DT significant_JJ decrease_NN in_IN cell_NN viability_NN
          starting_VBG 24_CD h_NN after_IN treatment_NN compared_VBN to_TO untreated_JJ cells_NNS
          cultured_JJ for_IN 72_CD h_NN (_( Fig_NNP ._. 3_LS b_SYM )_) ._. Treatment_NNP of_IN CLENDO_NNP cells_NNS
          for_IN 48_CD h_NN with_IN S_NNP 1_CD P_NN at_IN either_DT 10_CD μM_NN or_CC 50_CD μM_NN concentrations_NNS
          did_VBD not_RB induce_VB CLENDO_NNP cell_NN death_NN (_( data_NNS not_RB shown_VBN )_) ._.
          Furthermore_RB ,_, pretreatment_NN of_IN CLENDO_NNP cells_NNS for_IN 30_CD min_NN with_IN
          S_NNP 1_CD P_NN did_VBD not_RB prevent_VB ceramide-_NN or_CC TNFα-induced_NNP apoptosis_NNS
          (_( data_NNS not_RB shown_VBN )_) ._. As_IN with_IN TNFα_NNP treatment_NN ,_, application_NN of_IN
          ceramide_NN to_TO CLENDO_NNP cells_NNS resulted_VBD in_IN oligonucleosomal_NN DNA_NNP
          fragmentation_NN within_IN 12_CD h_NN ,_, thus_RB confirming_VBG apoptosis_NNS as_IN
          the_DT mechanism_NN of_IN cell_NN death_NN (_( see_VB Fig_NNP ._. 2_LS b_SYM ,_, lane_NN 6_CD )_) ._.
        
        
          Acute_NNP activation_NN of_IN the_DT mitogen-activated_JJ protein_NN
          kinase_NN superfamily_RB by_IN TNFα_NNP and_CC ceramide_NN
          Substantial_NNP data_NNS support_VBP the_DT notion_NN that_DT ceramide_NN
          serves_VBZ as_IN an_DT upstream_RB signaling_VBG molecule_NN in_IN the_DT
          activation_NN of_IN other_JJ signaling_VBG pathways_NNS such_JJ as_IN the_DT
          mitogen-activated_JJ protein_NN kinase_NN (_( MAPK_NNP )_) superfamily_RB [_NN 33_CD
          ]_NN ._. In_IN the_DT present_JJ study_NN quantitative_JJ measures_NNS were_VBD
          performed_VBN on_IN members_NNS of_IN the_DT MAPK_NNP superfamily_RB using_VBG
          antibodies_NNS that_WDT recognize_VBP only_RB the_DT phosphorylated_JJ ,_, and_CC
          presumptively_RB active_JJ ,_, forms_NNS of_IN ERK_NNP ,_, JNK_NNP ,_, and_CC p_NN 38_CD ._. Western_JJ
          blot_NN analysis_NN confirmed_VBD that_IN all_DT three_CD members_NNS of_IN the_DT
          MAPK_NNP superfamily_RB were_VBD transiently_RB activated_VBN by_IN treatment_NN
          with_IN TNFα_NNP (_( Fig_NNP ._. 4_LS a_DT )_) ._. The_DT levels_NNS of_IN phospho-_NN ERKs_NNP increased_VBD
          within_IN 5_CD min_NN of_IN TNFα_NNP treatment_NN ,_, peaked_VBN by_IN 10_CD min_NN and_CC
          decreased_VBN by_IN 30_CD min_NN (_( Fig_NNP ._. 4_LS b_SYM )_) ._. Phospho-p_NNP 38_CD levels_NNS peaked_VBD
          at_IN 5_CD min_NN and_CC showed_VBD an_DT equally_RB rapid_JJ decline_NN in_IN activity_NN ._.
          Levels_NNP of_IN phospho-_NN JNK_NNP activity_NN increased_VBD (_( P_NN <_NN 0_CD ._. 05_CD )_) by_IN
          10_CD min_NN and_CC remained_VBD elevated_VBD throughout_IN 30_CD min_NN of_IN
          incubation_NN with_IN TNFα_NNP (_( Fig_NNP ._. 4_LS b_SYM )_) ._.
          Since_IN ceramide_NN is_VBZ linked_VBN to_TO MAPK_NNP signaling_VBG pathways_NNS [_NN
          33_CD ]_NN we_PRP determined_VBD the_DT effect_NN of_IN treatment_NN of_IN CLENDO_NNP
          cells_NNS with_IN an_DT exogenous_JJ source_NN of_IN ceramide_NN ._. Treatment_NNP
          with_IN 50_CD μM_NN C_NNP 2_CD ceramide_NN failed_VBD to_TO activate_VBP the_DT ERK_NNP and_CC p_NN 38_CD
          MAPK_NNP pathways_NNS ._. However_RB ,_, treatment_NN with_IN C_NNP 2_CD ceramide_NN did_VBD
          activate_VBP the_DT JNK_NNP pathway_NN similar_JJ to_TO that_DT observed_VBD with_IN
          TNFα_NNP treatment_NN (_( Fig_NNP ._. 4_LS c_SYM )_) ._. Phospho-_NNP JNK_NNP was_VBD elevated_VBD with_IN
          in_IN 5_CD minutes_NNS after_IN C_NNP 2_CD addition_NN and_CC remained_VBD elevated_VBD for_IN
          at_IN least_JJS 30_CD min_NN ._.
        
        
          Glutathione_NNP attenuates_NNS TNFα-induced_NNP cell_NN
          death_NN
          Since_IN TNFRSF_NNP induces_VBZ cell_NN death_NN by_IN causing_VBG an_DT efflux_NN
          of_IN glutathione_NN (_( GSH_NNP )_) in_IN other_JJ cell_NN types_NNS [_NN 42_CD ]_NN we_PRP sought_VBD
          to_TO determine_VB if_IN pretreatment_NN of_IN CLENDO_NNP cells_NNS with_IN GSH_NNP
          would_MD attenuate_NN lethality_NN associated_VBN with_IN TNFα_NNP treatment_NN ._.
          CLENDO_NNP cells_NNS pretreated_JJ for_IN 30_CD min_NN with_IN GSH_NNP were_VBD
          significantly_RB less_RBR susceptible_JJ (_( P_NN <_NN 0_CD ._. 05_CD )_) to_TO the_DT
          lethal_JJ effects_NNS of_IN TNFα_NNP over_IN a_DT 48_CD h_NN period_NN than_IN cells_NNS
          treated_VBN with_IN TNFα_NNP alone_RB (_( Fig_NNP ._. 5_LS )_) ._. Treatment_NNP with_IN GSH_NNP
          alone_RB had_VBD no_DT effect_NN on_IN the_DT CLENDO_NNP cell_NN viability_NN ._.
        
      
      
        Discussion_NNP
        Treatment_NNP of_IN animals_NNS with_IN PGF_NNP 
        2_CD α_NN or_CC its_PRP$ analogs_NNS results_NNS in_IN endothelial_NN
        cell_NN death_NN 
        in_IN vivo_NN [_NN 43_CD ]_NN ,_, suggesting_VBG that_IN PGF_NNP 
        2_CD α_NN may_MD have_VB a_DT direct_JJ effect_NN on_IN CLENDO_NNP
        cells_NNS ._. However_RB ,_, the_DT microvasculature_NN of_IN the_DT CL_NNP is_VBZ composed_VBN
        of_IN a_DT number_NN of_IN different_JJ luteal_NN endothelial_NN cell_NN types_NNS ;_: the_DT
        most_RBS common_NN of_IN which_WDT does_VBZ not_RB express_VB mRNA_NN encoding_VBG the_DT PGF_NNP
        
        2_LS α_NN receptor_NN FP_NNP [_NN 35_CD 44_CD ]_NN ._. This_DT
        particular_JJ endothelial_NN cell_NN type_NN is_VBZ unresponsive_JJ to_TO PGF_NNP 
        2_CD α_NN treatment_NN [_NN 35_CD ]_NN in_IN that_DT PGF_NNP 
        2_CD α_NN treatment_NN does_VBZ not_RB increase_VB the_DT
        secretion_NN of_IN monocyte_NN chemoattractant_NN protein-_NN 1_CD [_NN 35_CD ]_NN or_CC
        stimulate_VB well-recognized_JJ PGF_NNP 
        2_CD α_NN -_: responsive_JJ intracellular_NN signaling_VBG
        pathways_NNS [_NN 35_CD 36_CD ]_NN ._. Lehmann_NNP ,_, 
        et_CC al_NN ._. [_NN 45_CD ]_NN recently_RB characterized_VBD
        a_DT predominant_NN cytokeratin-negative_JJ endothelial_NN cell_NN type_NN in_IN
        the_DT bovine_JJ CL_NNP in_IN addition_NN to_TO a_DT "_'' rare_JJ "_'' cytokeratin-positive_JJ
        endothelial_NN cell_NN type_NN ._. These_DT two_CD cell_NN populations_NNS may_MD have_VB
        different_JJ functional_JJ capacities_NNS in_IN that_IN they_PRP differ_VBP in_IN
        their_PRP$ expression_NN of_IN FP_NNP [_NN 44_CD 45_CD ]_NN ,_, as_RB well_RB as_IN their_PRP$
        secreted_JJ cytokine_NN profiles_NNS [_NN 45_CD ]_NN ._. In_IN the_DT present_JJ studies_NNS
        PGF_NNP 
        2_CD α_NN was_VBD incapable_JJ of_IN directly_RB inducing_VBG
        apoptosis_NNS of_IN CLENDO_NNP cells_NNS ._. Consequently_RB ,_, there_EX is_VBZ some_DT
        question_NN as_IN to_TO whether_IN PGF_NNP 
        2_CD α_NN has_VBZ any_DT direct_JJ effect_NN on_IN CLENDO_NNP cell_NN
        function_NN ,_, which_WDT directed_VBD our_PRP$ attention_NN toward_IN other_JJ known_VBN
        luteolytic_JJ factors_NNS (_( 
        i_NNP ._. e_SYM ._. ,_, cytokines_NNS )_) ._.
        A_DT primary_JJ objective_NN of_IN this_DT study_NN was_VBD to_TO determine_VB which_WDT
        cytokines_NNS initiate_VBP CLENDO_NNP cell_NN death_NN ._. Of_IN the_DT various_JJ
        cytokines_NNS tested_VBN (_( TNFα_NNP ,_, IFNγ_NNP ,_, or_CC sFasL_NN )_) ,_, TNFα_NNP was_VBD the_DT only_RB
        potent_JJ initiator_NN of_IN CLENDO_NNP cell_NN death_NN ._. Time_NN course_NN analysis_NN
        suggested_VBD that_IN the_DT loss_NN of_IN viability_NN was_VBD rapid_JJ (_( Fig_NNP 1_CD aand_NN
        2_CD a_DT )_) and_CC progressive_JJ ,_, with_IN only_RB 30_CD %_NN of_IN the_DT cells_NNS remaining_VBG
        non-apoptotic_JJ by_IN 72_CD hr_NN post-treatment_JJ ._. The_DT rapid_JJ induction_NN
        of_IN apoptosis_NNS in_IN response_NN to_TO TNFα_NNP is_VBZ similar_JJ to_TO the_DT
        microvascular_NN endothelial_NN cell_NN death_NN which_WDT was_VBD observed_VBN by_IN
        Friedman_NNP and_CC colleagues_NNS [_NN 29_CD ]_NN at_IN higher_JJR concentrations_NNS of_IN
        TNFα_NNP ._. One_CD receptor_NN for_IN TNFα_NNP ,_, TNF-RI_NNP is_VBZ expressed_VBN throughout_IN
        the_DT bovine_JJ estrous_JJ cycle_NN [_NN 46_CD ]_NN ,_, but_CC is_VBZ more_RBR abundantly_RB
        expressed_VBN by_IN the_DT endothelial_NN cell_NN component_NN than_IN in_IN
        steroidogenic_JJ cells_NNS [_NN 29_CD ]_NN ._.
        At_IN physiological_JJ concentrations_NNS ,_, TNFα_NNP induces_VBZ cell_NN death_NN
        in_IN most_JJS TNFα_NNP responsive_JJ cell_NN types_NNS via_IN apoptosis_NNS ._. This_DT
        effect_NN was_VBD evident_JJ in_IN CLENDO_NNP cells_NNS by_IN hallmark_NN features_NNS of_IN
        apoptosis_NNS including_VBG nuclear_JJ chromatin_NN condensation_NN ,_,
        formation_NN of_IN apoptotic_JJ bodies_NNS and_CC it_PRP was_VBD confirmed_VBN by_IN an_DT
        increase_NN in_IN caspase-_NN 3_CD activity_NN and_CC oligonucleosomal_NN DNA_NNP
        fragmentation_NN ._. Active_JJ caspase-_NN 3_CD is_VBZ a_DT functional_JJ requirement_NN
        of_IN spontaneous_JJ luteal_NN regression_NN in_IN that_DT
        caspase-_NN 3_CD -_: deficient_NN mice_NNS retain_VBP CL_NNP for_IN a_DT longer_JJR period_NN of_IN
        time_NN than_IN wild_JJ type_NN littermates_NNS [_NN 47_CD ]_NN ._. However_RB ,_, this_DT
        murine_NN study_NN did_VBD not_RB delineate_NN which_WDT luteal_NN cells_NNS were_VBD
        affected_VBN ._. Whether_IN caspase-_NN 3_CD activity_NN is_VBZ a_DT required_JJ
        component_NN of_IN the_DT luteal_NN endothelial_NN cell_NN apoptosis_NNS paradigm_NN
        remains_VBZ to_TO be_VB determined_VBN ._.
        Unlike_IN TNFα_NNP ,_, other_JJ cytokines_NNS (_( IFNγ_NNP or_CC sFasL_NN )_) or_CC Fas_NNP
        activating_VBG antibodies_NNS had_VBD little_JJ effect_NN on_IN the_DT endothelial_NN
        cell_NN viability_NN ._. It_PRP is_VBZ not_RB readily_RB apparent_JJ why_WRB these_DT
        cytokines_NNS failed_VBD to_TO induce_VB CLENDO_NNP cell_NN death_NN ,_, but_CC one_CD
        explanation_NN may_MD be_VB the_DT lack_NN of_IN cognate_NN receptors_NNS on_IN the_DT
        cell_NN surface_NN ._. Co-treatment_NNP of_IN luteal_NN endothelial_NN cells_NNS with_IN
        IFNγ_NNP augmented_JJ TNFα-induced_NNP death_NN ,_, a_DT result_NN that_WDT may_MD be_VB
        explained_VBN in_IN two_CD ways_NNS ._. First_LS ,_, it_PRP is_VBZ possible_JJ that_IN the_DT
        signaling_VBG events_NNS initiated_VBN by_IN the_DT combined_VBN treatment_NN of_IN
        TNFα_NNP and_CC IFNγ_NNP are_VBP more_RBR potent_JJ at_IN activating_VBG endothelial_NN
        cell_NN death_NN than_IN TNFα_NNP alone_RB ._. Alternatively_RB ,_, IFNγ_NNP may_MD
        increase_VB the_DT expression_NN of_IN the_DT death_NN domain_NN containing_VBG
        TNF-RI_NNP and_CC thus_RB increase_VB the_DT luteal_NN endothelial_NN cell_NN death_NN
        susceptibility_NN upon_IN exposure_NN to_TO TNFα_NNP ._. This_DT later_JJ suggestion_NN
        has_VBZ been_VBN shown_VBN to_TO be_VB the_DT case_NN in_IN luteal_NN steroidogenic_JJ cells_NNS
        for_IN another_DT death_NN receptor_NN ,_, in_IN which_WDT Fas_NNP mRNA_NN expression_NN
        increased_VBD in_IN response_NN to_TO IFNγ_NNP treatment_NN [_NN 20_CD 22_CD ]_NN ._.
        Interestingly_RB ,_, we_PRP find_VBP that_IN two_CD different_JJ cytokines_NNS (_( 
        i_NNP ._. e_SYM ._. sFasL_NN and_CC TNFα_NNP )_) can_MD activate_VBP the_DT
        sphingomyelin_NN pathway_NN in_IN two_CD distinct_JJ CL_NNP cell_NN types_NNS ._. TNFα_NNP
        elevates_VBZ ceramide_NN in_IN CLENDO_NNP cells_NNS ,_, whereas_IN sFasL_NN elevates_VBZ
        ceramide_NN in_IN primary_JJ luteal_NN steroidogenic_JJ cells_NNS [_NN 26_CD ]_NN ._.
        Ceramide_NNP treatment_NN induces_VBZ apoptosis_NNS in_IN both_DT cell_NN types_NNS ,_,
        suggesting_VBG that_IN the_DT sphingomyelin_NN pathway_NN may_MD be_VB a_DT common_JJ
        mediator_NN of_IN cell_NN death_NN among_IN distinct_JJ cell_NN types_NNS within_IN the_DT
        CL_NNP ._.
        Sphingomyelin_NNP content_NN and_CC luteal_NN cell_NN membrane_NN fluidity_NN
        decrease_NN during_IN luteolysis_NNS 
        in_IN vivo_NN [_NN 48_CD 49_CD 50_CD 51_CD ]_NN ._. Ceramide_NNP ,_, a_DT
        product_NN of_IN sphingomyelin_NN hydrolysis_NNS ,_, is_VBZ a_DT potent_JJ
        stress-activated_JJ second_JJ messenger_NN and_CC is_VBZ well_RB established_VBN
        as_IN a_DT functional_JJ component_NN of_IN death_NN receptor-mediated_JJ
        apoptosis_NNS [_NN 52_CD 53_CD 54_CD ]_NN ._. Upon_IN treatment_NN of_IN CLENDO_NNP cells_NNS
        with_IN TNFα_NNP ,_, we_PRP observed_VBD a_DT rapid_JJ and_CC sustained_VBN increase_NN in_IN
        the_DT production_NN of_IN ceramide_NN ,_, suggesting_VBG that_IN the_DT
        sphingomyelin_NN pathway_NN is_VBZ present_JJ and_CC active_JJ in_IN these_DT cells_NNS ._.
        Exogenous_NNP ceramide_NN induced_VBD CLENDO_NNP cell_NN oligonucleosomal_NN DNA_NNP
        fragmentation_NN and_CC reduced_VBN cell_NN viability_NN in_IN a_DT manner_NN
        consistent_JJ with_IN TNFα_NNP treatment_NN ._. The_DT exact_JJ role_NN and_CC
        functional_JJ significance_NN of_IN ceramide_NN production_NN in_IN response_NN
        to_TO TNFα_NNP in_IN CLENDO_NNP cell_NN apoptosis_NNS are_VBP not_RB presently_RB known_VBN ._.
        However_RB ,_, in_IN some_DT cell_NN types_NNS ,_, ceramide_NN production_NN has_VBZ been_VBN
        placed_VBN at_IN the_DT top_NN of_IN molecular_JJ ordering_VBG schemes_NNS for_IN several_JJ
        signaling_VBG cascades_NNS as_RB well_RB as_IN increase_NN in_IN reactive_JJ oxygen_NN
        species_NNS ._. Substantial_NNP evidence_NN exists_VBZ to_TO suggest_VB that_IN
        stress-induced_JJ apoptosis_NNS is_VBZ mediated_JJ through_IN activation_NN of_IN
        MAPK_NNP signaling_VBG pathways_NNS in_IN non-ovarian_JJ cell_NN types_NNS ._. While_IN
        these_DT pathways_NNS are_VBP activated_VBN in_IN luteal_NN steroidogenic_JJ cells_NNS
        by_IN diverse_JJ cell_NN stressors_NNS ,_, including_VBG cytokines_NNS [_NN 55_CD ]_NN ,_, no_DT
        such_JJ detailed_JJ studies_NNS have_VBP been_VBN completed_VBN to_TO date_NN in_IN the_DT
        endothelial_NN cell_NN component_NN of_IN the_DT CL_NNP ._. In_IN the_DT present_JJ study_NN
        we_PRP provide_VBP evidence_NN that_IN TNFα_NNP and_CC a_DT by-product_JJ of_IN TNFα_NNP
        signaling_VBG ,_, ceramide_NN ,_, both_DT have_VBP the_DT capacity_NN to_TO activate_VBP
        members_NNS of_IN the_DT MAPK_NNP family_NN ._. Activation_NNP of_IN MAPK_NNP stress_NN
        pathways_NNS can_MD alter_VB cell_NN viability_NN through_IN multiple_JJ
        mechanisms_NNS ._. For_IN example_NN ,_, TNFα_NNP can_MD activate_VBP transcription_NN
        factors_NNS that_WDT bind_NN genomic_JJ DNA_NNP and_CC initiate_VB gene_NN expression_NN
        of_IN pro-apoptotic_JJ genes_NNS [_NN 56_CD 57_CD ]_NN ._.
        A_DT number_NN of_IN studies_NNS provide_VBP evidence_NN that_IN the_DT luteolytic_JJ
        process_NN may_MD involve_VB a_DT rapid_JJ and_CC sustained_VBN increase_NN in_IN ROS_NNP [_NN
        58_CD 59_CD ]_NN ._. Other_JJ studies_NNS demonstrate_VBP that_DT luteal_NN regression_NN
        is_VBZ associated_VBN with_IN a_DT dramatic_JJ decrease_NN in_IN the_DT mRNAs_NNS
        encoding_VBG enzymes_NNS responsible_JJ for_IN regulating_VBG the_DT
        intracellular_NN redox_NN state_NN [_NN 60_CD ]_NN ._. Death_NN induced_VBN by_IN TNFα_NNP is_VBZ
        also_RB reportedly_RB mediated_JJ by_IN an_DT increase_NN in_IN ROS_NNP ,_, an_DT event_NN
        correlated_JJ with_IN a_DT marked_VBN decrease_NN in_IN the_DT vital_JJ
        intracellular_NN ROS_NNP scavenger_NN GSH_NNP ._. Activation_NNP of_IN TNF-RI_NNP and_CC
        other_JJ death_NN domain_NN containing_VBG receptors_NNS of_IN the_DT TNF_NNP receptor_NN
        superfamily_RB have_VBP been_VBN shown_VBN to_TO cause_VB an_DT efflux_NN of_IN GSH_NNP ,_,
        which_WDT contributes_VBZ to_TO the_DT apoptotic_JJ process_NN [_NN 42_CD 61_CD ]_NN ._.
        Provision_NNP of_IN GSH_NNP in_IN the_DT present_JJ study_NN reduced_VBD the_DT
        deleterious_JJ effects_NNS of_IN TNFα_NNP on_IN CLENDO_NNP cells_NNS ._. We_PRP suggest_VBP
        that_IN one_CD mechanism_NN by_IN which_WDT TNFα_NNP induces_VBZ CLENDO_NNP cell_NN death_NN
        is_VBZ through_IN the_DT formation_NN of_IN ROS_NNP ,_, a_DT result_NN that_WDT may_MD stem_VB
        from_IN depletion_NN of_IN GSH_NNP stores_NNS in_IN CLENDO_NNP cells_NNS ._. Provision_NNP of_IN
        exogenous_JJ GSH_NNP may_MD restore_VB the_DT redox_NN state_NN disrupted_VBN by_IN TNFα_NNP
        treatment_NN ._. These_DT findings_NNS lend_VBP support_NN to_TO the_DT notion_NN that_IN
        TNFα_NNP contributes_VBZ to_TO luteolysis_NNS by_IN initiating_VBG formation_NN of_IN
        endothelial_NN cell-derived_JJ ROS_NNP ._.
        In_IN this_DT study_NN ,_, we_PRP have_VBP corroborated_JJ findings_NNS of_IN Friedman_NNP
        
        et_CC al_NN [_NN 29_CD ]_NN that_IN TNFα_NNP is_VBZ a_DT potent_JJ
        apoptotic_JJ stimulus_NN of_IN primary_JJ luteal_NN microvascular_NN
        endothelial_NN cells_NNS and_CC extend_VB these_DT findings_NNS by_IN
        characterizing_VBG the_DT activation_NN of_IN several_JJ stress-activated_JJ
        signal_NN transduction_NN pathways_NNS in_IN response_NN to_TO TNFα_NNP treatment_NN
        of_IN cultured_JJ endothelial_NN cells_NNS ._. Whether_IN these_DT acute_JJ
        signaling_VBG events_NNS are_VBP linked_VBN to_TO ,_, and_CC functionally_RB required_VBN
        for_IN ,_, down_RB stream_NN apoptotic_JJ mechanisms_NNS remain_VBP to_TO be_VB
        determined_VBN ._. Furthermore_RB ,_, the_DT possibility_NN that_IN alterations_NNS
        in_IN GSH_NNP metabolism_NN or_CC cellular_JJ flux_NN ,_, and_CC thus_RB the_DT redox_NN
        state_NN ,_, within_IN CLENDOs_NNP result_NN from_IN exposure_NN to_TO TNFα_NNP needs_VBZ to_TO
        be_VB tested_VBN ._. These_DT experiments_NNS as_RB well_RB as_IN future_JJ studies_NNS
        designed_VBN to_TO identify_VB the_DT enzymatic_JJ pathway_NN (_( s_VBZ )_) and_CC in_IN which_WDT
        cellular_JJ compartment_NN (_( s_VBZ )_) ceramide_NN is_VBZ generated_VBN in_IN luteal_NN
        microvascular_NN endothelial_NN cells_NNS in_IN response_NN to_TO TNFα_NNP
        treatment_NN should_MD help_VB determine_VB which_WDT ,_, if_IN any_DT ,_, of_IN the_DT
        acutely_RB activated_VBN signal_NN transduction_NN pathways_NNS contribute_VBP
        to_TO luteal_NN endothelial_NN cell_NN apoptosis_NNS ._. In_IN conclusion_NN ,_, TNFα_NNP
        activates_NNS several_JJ stress-activated_JJ signaling_VBG pathways_NNS that_WDT
        may_MD facilitate_VB GSH_NNP efflux_NN ,_, and_CC thus_RB increase_VB ROS_NNP and_CC
        subsequent_JJ cell_NN death_NN ._.
      
    
  
